News

“The results of the SIRIUS II study show ularitide to be well-tolerated and indicate clear, dose-dependent favorable effects in treating the symptoms of ADHF without compromising kidney function,”

The purpose of the study, published in the Journal of Virology, was to compare the efficacy of LC16m8 with that of its parent strain, the Lister strain of

The letter states that Dacogen injection is approvable pending the FDA’s review of a requested analysis of the transfusion requirements of patients enrolled in the completed phase III

The companies are currently awaiting an FDA decision on whether or not to approve Modafinil for an indication to treat ADHD in children and adolescents. Cephalon submitted the

This acquisition adds to the company’s growing vaccines presence in the US, following GSK’s recent purchase of Corixa Corporation, a developer of innovative vaccine adjuvants that increase immune

The submission is based primarily on the 24-week results of a multi-center, phase III study. In the trial, patients who received a single course of two infusions of

Production at Chiron’s facility in Liverpool, UK had been halted in October 2004 after regulators raised contamination concerns about the plant’s manufacturing process. The vaccine maker may now

“Our goal to provide Aricept to people with severe Alzheimer’s disease is consistent with Eisai’s human health care mission to improve the lives of patients and their families,”

The introduction of GSK’s Fluarix, indicated for adults 18 and older against influenza disease, is the next immediate step in that commitment. Fluarix, currently distributed in 79 countries,